851 related articles for article (PubMed ID: 18927299)
21. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study.
Bollet MA; Thibault F; Bouillon K; Meunier M; Sigal-Zafrani B; Savignoni A; Diéras V; Nos C; Salmon R; Fourquet A;
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):13-8. PubMed ID: 17449193
[TBL] [Abstract][Full Text] [Related]
22. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
[TBL] [Abstract][Full Text] [Related]
23. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
[TBL] [Abstract][Full Text] [Related]
24. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
[TBL] [Abstract][Full Text] [Related]
25. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
27. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas.
Toms AP; White LM; Kandel R; Bleakney RR; Noseworthy M; Lee S; Blackstein ME; Wunder J
Acta Radiol; 2009 Jun; 50(5):512-20. PubMed ID: 19431058
[TBL] [Abstract][Full Text] [Related]
28. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
Schrier BP; Peters M; Barentsz JO; Witjes JA
Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
[TBL] [Abstract][Full Text] [Related]
30. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
[TBL] [Abstract][Full Text] [Related]
31. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
Loo CE; Teertstra HJ; Rodenhuis S; van de Vijver MJ; Hannemann J; Muller SH; Peeters MJ; Gilhuijs KG
AJR Am J Roentgenol; 2008 Nov; 191(5):1331-8. PubMed ID: 18941065
[TBL] [Abstract][Full Text] [Related]
32. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Schaafsma BE; van de Giessen M; Charehbili A; Smit VT; Kroep JR; Lelieveldt BP; Liefers GJ; Chan A; Löwik CW; Dijkstra J; van de Velde CJ; Wasser MN; Vahrmeijer AL
Clin Cancer Res; 2015 Feb; 21(3):577-84. PubMed ID: 25473002
[TBL] [Abstract][Full Text] [Related]
33. Assessment of clinical response after two cycles of primary chemotherapy in breast cancer.
Beresford MJ; Stott D; Makris A
Breast Cancer Res Treat; 2008 May; 109(2):337-42. PubMed ID: 17624608
[TBL] [Abstract][Full Text] [Related]
34. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
Chen X; Moore MO; Lehman CD; Mankoff DA; Lawton TJ; Peacock S; Schubert EK; Livingston RB
Acad Radiol; 2004 Oct; 11(10):1115-24. PubMed ID: 15530804
[TBL] [Abstract][Full Text] [Related]
35. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
[TBL] [Abstract][Full Text] [Related]
36. Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer.
Soliman H; Gunasekara A; Rycroft M; Zubovits J; Dent R; Spayne J; Yaffe MJ; Czarnota GJ
Clin Cancer Res; 2010 May; 16(9):2605-14. PubMed ID: 20406836
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast.
Drew PJ; Kerin MJ; Mahapatra T; Malone C; Monson JR; Turnbull LW; Fox JN
Eur J Surg Oncol; 2001 Nov; 27(7):617-20. PubMed ID: 11669587
[TBL] [Abstract][Full Text] [Related]
38. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
39. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
40. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy.
Straver ME; Loo CE; Rutgers EJ; Oldenburg HS; Wesseling J; Vrancken Peeters MJ; Gilhuijs KG
Ann Surg; 2010 Apr; 251(4):701-7. PubMed ID: 20224378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
